Table 3.
Prospective and selected retrospective studies comparing autologous stem cell transplantation to allogeneic stem cell transplantation
| Study | Comments | Type of transplantation | n | CR, % | PFS | OS | TRM, % |
|---|---|---|---|---|---|---|---|
| Garban et al. [56] | Prospective randomized trial | Tandem-ASCT | 219 | 51 (CR + VGPR) | 30 months (EFS) | 741 | 5 |
| ASCT followed by allo-SCT | 65 | 62 (CR + VGPR) | 25 months (EFS) | 35 | 11 | ||
| Bruno et al. [57••] | Prospective randomized trial | Tandem-ASCT | 82a (46) | 26 | 2 | 58 months | |
| ASCT followed by allo-SCT | 60a (58) | 55 | 10 | NR | |||
| Alyea et al. [50] | Single-institution retrospective analysis; T-cell-depleted allo-SCT | ASCT | 166 | NA | 28% (4 years) | 41% (4 years) | 13 |
| Allo-SCT | 66 | NA | 18% (4 years) | 39% (4 years) | 24 | ||
| Bjorkstrand et al. [49] | EBMTR analysis; groups matched for sex and number of treatment lines before SCT | ASCT | 189 | 40 | 22 months | 34 months | 13 |
| Allo-SCT | 189 | 48 | 12 months | 18 months | 41 | ||
| Arora et al. [48] | Single-institution retrospective analysis | ASCT | 70 | 34 | 18% (4 years) | 50% (4 years) | 6 |
| Allo-SCT | 17 | 64 | 32% (4 years) | 64% (4 years) | 31 | ||
| Kuruvilla et al. [51] | Single-institution retrospective analysis | ASCT | 86 | 25 (CR + VGPR) | 15% (10 years) | 31% (10 years) | 14 |
| Allo-SCT | 72 | 38 (CR + VGPR) | 31% (10 years) | 40% (10 years) | 22 |
ASCT, autologous stem cell transplantation; allo-SCT, allogeneic stem cell transplantation; CR, complete response; EBMTR, European Bone Marrow Transplantation Registry; EFS, event-free survival; NA, not available; NR, not recommended; OS, overall survival; PFS, progression-free survival; TRM, transplantation-related mortality; VAD, vincristine, doxorubicin, dexamethasone; VGPR, very good partial response.
a
Patients completing assigned treatment.